Third Harmonic Bio, Inc. (THRD)
(Delayed Data from NSDQ)
$12.10 USD
+0.29 (2.46%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $12.07 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
THRD 12.10 +0.29(2.46%)
Will THRD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for THRD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for THRD
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
THRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Other News for THRD
Stifel starts Third Harmonic at buy, cites mast cell disease approach
Buy Rating for Third Harmonic Bio: Innovative KIT Inhibitor THB335 Targets Untapped Inflammatory Disease Market
Third Harmonic Bio initiated with bullish view at Stifel, here's why
Third Harmonic Bio initiated with bullish view at Raymond James, here's why
Third Harmonic Bio Announces Executive Changes and Voting Results